 Cara Therapeutics Inc NASDAQ: CARA is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. KORSUVA injection is a kappa opioid receptor agonist that targets the bodys peripheral nervous system. 